Department and Clinic of Internal Medicine, Angiology, and Physical Medicine, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Batorego 15 St., 41-902 Bytom, Poland.
Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Jordana 38 St., 41-800 Zabrze, Poland.
Int J Environ Res Public Health. 2021 Nov 15;18(22):11970. doi: 10.3390/ijerph182211970.
Diabetes mellitus (DM) is a strong risk factor for the development of cardiovascular diseases such as coronary heart disease, cerebrovascular disease, and peripheral arterial disease (PAD). In the population of people living with DM, PAD is characterised by multi-level atherosclerotic lesions as well as greater involvement of the arteries below the knee. DM is also a factor that significantly increases the risk of lower limb amputation. Percutaneous balloon angioplasty with or without stent implantation is an important method of the treatment for atherosclerotic cardiovascular diseases, but restenosis is a factor limiting its long-term effectiveness. The pathogenesis of atherosclerosis in the course of DM differs slightly from that in the general population. In the population of people living with DM, more attention is drawn to such factors as inflammation, endothelial dysfunction, platelet dysfunction, blood rheological properties, hypercoagulability, and additional factors stimulating vascular smooth muscle cell proliferation. DM is a risk factor for restenosis. The purpose of this paper is to provide a review of the literature and to present the most important information on the current state of knowledge on mechanisms and the clinical significance of restenosis and in-stent restenosis in patients with DM, especially in association with the endovascular treatment of PAD. The role of such processes as inflammation, neointimal hyperplasia and neoatherosclerosis, allergy, resistance to antimitotic drugs used for coating stents and balloons, genetic factors, and technical and mechanical factors are discussed. The information on restenosis collected in this publication may be helpful in planning further research in this field, which may contribute to the formulation of more and more precise recommendations for the clinical practice.
糖尿病(DM)是冠心病、脑血管病和外周动脉疾病(PAD)等心血管疾病的强烈危险因素。在患有 DM 的人群中,PAD 的特征是多水平动脉粥样硬化病变以及膝下动脉的更大受累。DM 也是导致下肢截肢风险显著增加的因素。经皮球囊血管成形术联合或不联合支架植入是治疗动脉粥样硬化性心血管疾病的重要方法,但再狭窄是限制其长期效果的因素。DM 患者的动脉粥样硬化发病机制与普通人群略有不同。在患有 DM 的人群中,更关注炎症、内皮功能障碍、血小板功能障碍、血液流变学特性、高凝状态以及刺激血管平滑肌细胞增殖的其他因素。DM 是再狭窄的危险因素。本文的目的是对文献进行综述,并介绍有关 DM 患者再狭窄和支架内再狭窄的机制和临床意义的最新知识状态的重要信息,特别是与 PAD 的血管内治疗相关的信息。讨论了炎症、新生内膜增生和新动脉粥样硬化、过敏、对用于涂层支架和球囊的抗有丝分裂药物的耐药性、遗传因素以及技术和机械因素等过程的作用。本文收集的再狭窄信息可能有助于规划该领域的进一步研究,这可能有助于制定越来越精确的临床实践建议。
Int J Environ Res Public Health. 2021-11-15
Curr Drug Targets Cardiovasc Haematol Disord. 2004-9
Ont Health Technol Assess Ser. 2010
J Cardiovasc Surg (Torino). 2017-8
Catheter Cardiovasc Interv. 2018-7
Front Cardiovasc Med. 2025-7-18
Mol Cell Proteomics. 2025-4-24
Int J Mol Sci. 2021-9-23
Catheter Cardiovasc Interv. 2022-2
Arterioscler Thromb Vasc Biol. 2021-9